NCT01003405撤回3 期
A Open-label, Long-term Extension Study of KUC-7483 in Patients With Overactive Bladder
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- The long-term safety of KUC-7483 for the treatment of overactive bladder.
研究概览
简要总结
To investigate the long-term safety, efficacy and pharmacokinetics of KUC-7483 in patients with overactive bladder.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have successfully completed the Phase III double-blind study.
排除标准
- •Patients with serious adverse events or clinically significant adverse events in the Phase III double-blind study.
研究组 & 干预措施
KUC-7483
Experimental
干预措施: KUC-7483 (Drug)
结局指标
主要结局
The long-term safety of KUC-7483 for the treatment of overactive bladder.
时间窗: 52 weeks
次要结局
- The long-term efficacy of KUC-7483 for the treatment of overactive bladder.(52 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male VolunteersHealthyNCT02259933Boehringer Ingelheim35
已完成
3 期
An Open-label, Non-controlled Study of KHK4827 in Subjects With PsoriasisPsoriasisNCT01782937Kyowa Kirin Co., Ltd.30
已完成
3 期
Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined DyslipidemiaDyslipidemiasHypercholesterolemiaNCT00330876Kowa Research Europe545
已完成
3 期
A Phase III Long Term Study of K-877 Extended Release TabletDyslipidemiasNCT04716595Kowa Company, Ltd.121
已完成
3 期
A Long-term Trial of OPC-34712 in Patients With SchizophreniaSchizophreniaNCT01456897Otsuka Pharmaceutical Co., Ltd.282